APL with PML-RARA (APLPMLRARA)

Overview

Acute promyelocytic leukemia (APL) driven by the PML-RARA fusion, arising from the t(15;17)(q22;q12) translocation. It sits within the AML with recurrent genetic abnormalities (AMLRGA) branch of OncoTree and is classified as a Myeloid tissue malignancy. APL with PML-RARA is historically significant as one of the first cancers successfully treated with molecularly targeted therapy (all-trans retinoic acid plus arsenic trioxide), and is cited in the preclinical modeling literature as the original proof-of-concept for co-clinical trial design.

Cohorts in the corpus

  • No dedicated APL dataset pages in the current corpus.

Recurrent alterations

  • APL is defined by the PML-RARA fusion resulting from t(15;17); this genomic rearrangement is the canonical driver event for this OncoTree node.
  • APL with PML-RARA is cited as the original co-clinical trial success story — synchronized mouse and human studies that established the proof-of-concept for parallel preclinical/clinical trial design PMID:23999436.

Subtypes

  • APL with PML-RARA is itself a molecularly defined subtype of AML with recurrent genetic abnormalities (AMLRGA); no further molecular subtypes are discussed in the current corpus.

Therapeutic landscape

  • ATRA (all-trans retinoic acid) and arsenic trioxide combination is the established standard-of-care for PML-RARA-driven APL; this disease is cited as the paradigmatic example of molecularly targeted therapy success, motivating the co-clinical trial approach described in PMID:23999436.

Sources

  • PMID:23999436 — Herter-Sprie et al. review citing APL as the original co-clinical trial proof-of-concept.

This page was processed by crosslinker on 2026-05-09.